SNAP-8 (Acetyl Octapeptide-3)

Also known as: Acetyl octapeptide-3, Acetyl glutamyl heptapeptide-1

**Mechanism of Action** SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide designed as an extended analog of Argireline (Acetyl Hexapeptide-8). It competitively inhibits the interaction of SNAP-25 (synaptosomal-associated protein 25) with the SNARE complex, a key mediator of vesicle fusion and neurotransmitter release at the neuromuscular junction. By disrupting SNARE assembly, SNAP-8 reduces calcium-dependent exocytosis of acetylcholine, thereby attenuating muscle contraction. This mechanism is proposed to decrease the intensity of facial muscle movements underlying dynamic wrinkle formation. **Key Research Findings** Currently, no peer-reviewed studies indexed in PubMed are available for SNAP-8. Its mechanism is inferred from structural homology to Argireline, which has demonstrated dose-dependent inhibition of neurotransmitter release in vitro. Preclinical data (unpublished or proprietary) suggest enhanced potency compared to Argireline due to the additional amino acid residues, potentially improving binding affinity to SNAP-25. However, independent validation of efficacy, safety, and pharmacokinetics remains absent in the public scientific literature. **Clinical Relevance** SNAP-8 is classified as experimental, with no approved therapeutic or cosmetic indications. It is marketed in unregulated topical formulations as a "botox-like" alternative for wrinkle reduction, but clinical evidence supporting its efficacy or long-term safety is lacking. Regulatory status varies by jurisdiction; it is not FDA-approved for any use. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides